The submission of an IND application to the FDA is a critical regulatory step for NeuroBo Pharmaceuticals, indicating that the company is moving forward with its clinical development plans for DA-1726. This progress is typically viewed positively by investors, as it suggests potential future revenue streams and growth if the treatment is successful. The news directly impacts NeuroBo, as it pertains to their proprietary treatment, and the positive market reaction is likely to be sustained in the short term as investors anticipate the start of the Phase 1 trial.